Dexamethasone (EENT)

Drug class: Antineoplastic Agents

Usage of Dexamethasone (EENT)

Ophthalmic Inflammation

Symptomatic relief of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (e.g., allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides).

Treatment of chronic anterior uveitis.

Treatment of corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.

Bacterial Ophthalmic Infections

Used for anti-inflammatory properties in conjunction with appropriate anti-infective therapy in some bacterial infections of the eye; used in fixed combination with neomycin and polymyxin B sulfates or tobramycin when such combination therapy is indicated. If an ophthalmic corticosteroid is used in combination with an ophthalmic anti-infective, weigh benefits against risks. (See Infections under Cautions.)

Otic Inflammation

Symptomatic relief of corticosteroid-responsive inflammatory conditions of the ear canal (e.g., allergic otitis externa).

Bacterial Otic Infections

Used for anti-inflammatory properties in conjunction with ciprofloxacin for treatment of acute otitis externa and in pediatric patients with tympanostomy tubes for acute otitis media.

Used to reduce edema and inflammation in select cases of purulent and nonpurulent infective otitis externa.

If a corticosteroid is used alone or in combination with an otic anti-infective, weigh benefits against risks. (See Infections under Cautions.)

Relate drugs

How to use Dexamethasone (EENT)

Administration

Apply topically to the eye or ear.

Ophthalmic Administration

Apply topically to the eye as an ophthalmic ointment, solution, or suspension.

Not for injection.

Shake suspension well prior to each use.

Avoid contamination of preparation container.

Do not administer solutions or suspensions containing benzalkonium chloride while wearing soft contact lenses. Wait ≥15 minutes after instilling drops before inserting contact lenses. (See Advice to Patients.)

Otic Administration

Apply topically to the ear as an otic suspension or an ophthalmic solution.

Not for injection. Do not instill otic preparations into the eye.

May use Dexamethasone sodium phosphate ophthalmic solution in the ear.

Shake suspension well prior to each use.

To avoid dizziness that may result from instilling a cold preparation into the ear, warm the preparation by holding the bottle in the hands for 1–2 minutes prior to administration.

Clean and dry ear canal prior to administration; pH of otic preparations should be neutral or acidic.

Lie with the affected ear upward and instill drops. For pediatric patients with otitis media and tympanostomy tubes, pump the tragus 5 times to ease penetration of drops into the middle ear. For acute otitis externa, pull outer ear lobe upward and backward to facilitate entry of drug into ear canal.

Keep affected ear upward for ≥60 seconds following drug administration. If necessary, repeat procedure for the opposite ear.

Use otic corticosteroids sparingly to prevent an accumulation of excess debris in the ear canal.

Dosage

Commercially available alone or in fixed combination with anti-infectives; available as dexamethasone or dexamethasone sodium phosphate. Solution available as dexamethasone sodium phosphate; dosage expressed in terms of dexamethasone phosphate.

Pediatric Patients

Bacterial Ophthalmic Infections

Duration of therapy depends on the type and severity of the disease and response to therapy. Do not discontinue prematurely.

When discontinuing therapy, gradually taper dosing frequency to avoid exacerbation of the disease.

Dexamethasone 0.1% and Tobramycin 0.3% Ophthalmic Suspension

Children ≥2 years of age: Initial 24–48 hours, 1 or 2 drop(s) into the conjunctival sac of the affected eye(s) every 2 hours. Thereafter, 1 or 2 drops every 4–6 hours. Gradually reduce dosing frequency as infection improves.

Ophthalmic Ointment

Children ≥2 years of age: Apply a 1.25-cm ribbon into the conjunctival sac of the affected eye(s) up to 3 or 4 times daily.

Bacterial Otic Infections Acute Otitis Externa Otic Suspension (Dexamethasone 0.1% and Ciprofloxacin 0.3%)

Children ≥6 months of age: 4 drops into the affected ear(s) twice daily for 7 days.

Acute Otitis Media Otic Suspension (Dexamethasone 0.1% and Ciprofloxacin 0.3%)

Children ≥6 months of age with tympanostomy tubes: 4 drops into the affected ear(s) twice daily for 7 days.

Adults

Ophthalmic Inflammation and Bacterial Infections

Duration of therapy depends on the type and severity of the disease and response to therapy. Do not discontinue prematurely.

When discontinuing therapy, gradually taper dosing frequency to avoid exacerbation of the disease.

Dexamethasone 0.1% Ophthalmic Suspension

For mild inflammation: 1 or 2 drops into the conjunctival sac of the affected eye(s) up to 4–6 times daily.

For severe inflammation: 1 or 2 drops into the conjunctival sac of the affected eye(s) every hour. Taper dosing frequency as inflammation subsides.

Dexamethasone Sodium Phosphate 0.1% Ophthalmic Solution

Initially, 1 or 2 drops into the conjunctival sac of the affected eye(s) every hour during the day and every 2 hours during the night. When a favorable response is attained, decrease to 1 drop every 4 hours. May decrease to 1 drop 3 or 4 times daily to control symptoms.

Dexamethasone 0.1%, Neomycin 0.35%, and Polymyxin B Sulfates 10,000 units Ophthalmic Suspension

For mild inflammation: 1 or 2 drop(s) into the conjunctival sac of the affected eye(s) up to 4–6 times daily.

For severe inflammation: 1 or 2 drops into the conjunctival sac of the affected eye(s) hourly. As inflammation subsides, gradually reduce dosing frequency to discontinue.

Ophthalmic Ointment

Apply a 1.25-cm ribbon into the conjunctival sac of the affected eye(s) up to 3 or 4 times daily.

Dexamethasone 0.1% and Tobramycin 0.3% Ophthalmic Suspension

Initial 24–48 hours, 1 or 2 drops into the conjunctival sac of the affected eye(s) every 2 hours; thereafter, 1 or 2 drops every 4 to 6 hours. Gradually reduce dosing frequency as infection improves.

Ophthalmic Ointment

Apply a 1.25-cm ribbon into the conjunctival sac of the affected eye(s) up to 3 or 4 times daily.

Otic Inflammation Dexamethasone Sodium Phosphate 0.1% Ophthalmic Solution Otic

Initially, 3 or 4 drops of the ophthalmic solution into the ear canal 2 or 3 times daily. May reduce dosing frequency as symptoms improve. Gradually taper the drug when it is discontinued.

Alternatively, a cotton wick saturated with the ophthalmic solution may be packed into the ear canal; keep the wick moist with the ophthalmic solution; remove saturated wick from ear after 12 to 24 hours. Repeat as necessary.

Duration of treatment may range from a few days to several weeks.

Bacterial Otic Infections: Acute Otitis Externa Dexamethasone 0.1% and Ciprofloxacin 0.3% Otic

4 drops into the affected ear(s) twice daily for 7 days.

Special Populations

No special population dosage recommendations at this time.

Warnings

Contraindications

  • Known hypersensitivity to dexamethasone or any ingredient in the formulation.
    • Ophthalmic Preparations
  • Viral diseases of the cornea and conjunctiva (e.g., epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella).
  • Mycobacterial infection (e.g., ocular tuberculosis) of the eye.
  • Fungal disease of ocular structures.
    • Otic Preparations
  • Viral infections of the external ear canal (e.g., herpes simplex).
  • Perforation of the ear drum.
  • Fungal diseases of auricular structures.

    • Warnings/Precautions

    Warnings

    Ocular Effects

    Risk of glaucoma with possible damage to the optic nerve, defects in visual acuity and fields of vision, and posterior suBCapsular cataract formation with prolonged use of corticosteroids. Use with caution in patients with glaucoma because IOP may increase.

    If used for ≥10 days, monitor IOP routinely even though monitoring may be difficult in children and uncooperative patients.

    In conditions causing thinning of the cornea or sclera, perforations reported with use of topical corticosteroids.

    Use of high-dose corticosteroids may delay healing. Use after cataract surgery may delay healing and increase incidence of bleb formation.

    Infections

    Prolonged use may suppress the host response and thus increase the risk of secondary ocular infections.

    In acute purulent conditions of the eye or ear, corticosteroids may mask infection or enhance existing infection. (See Contraindications under Cautions.)

    Herpes Simplex

    Use of corticosteroids in the treatment of herpes simplex infections other than epithelial herpes simplex keratitis, in which corticosteroids are contraindicated, requires great caution; periodic slit-lamp microscopy is essential.

    General Precautions

    Evaluation of Ocular Condition

    Initial prescription or renewal of medication order beyond 8 g of 0.1% ointment or 20 mL of 0.1% suspension should be provided only after examination of the patient with the aid of magnification (e.g., slit lamp biomicroscopy, fluorescein staining where appropriate).

    Fungal Infections

    Long-term local corticosteroid application associated with development of fungal infections of the cornea. Consider possibility of fungal infection in patients with persistent corneal ulceration who have been or are receiving corticosteroid therapy.

    Corneal Reepithelialization

    Use of ophthalmic ointments may decrease rate of corneal reepithelialization.

    Use of Fixed Combination

    When used in fixed combination with ciprofloxacin, neomycin and polymyxin B sulfates, or tobramycin, consider the cautions, precautions, and contraindications associated with the concomitant agents.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in milk.

    Caution if used in nursing women.

    Dexamethasone sodium phosphate ophthalmic solution and dexamethasone in fixed combination with ciprofloxacin otic suspension: Manufacturers recommend discontinuing nursing or the drug.

    Pediatric Use

    Safety and efficacy of ophthalmic dexamethasone suspension or dexamethasone sodium phosphate solution not established.

    Safety and efficacy of ophthalmic dexamethasone in fixed combination with neomycin and polymyxin B sulfates not established.

    Safety and efficacy of ophthalmic dexamethasone in fixed combination with tobramycin not established in children <2 years of age.

    Safety and efficacy of otic dexamethasone suspension in fixed combination with ciprofloxacin not established in infants <6 months of age.

    Geriatric Use

    No substantial differences in safety or efficacy relative to younger patients.

    Common Adverse Effects

    Ophthalmic administration: Elevated IOP, posterior subcapsular cataract formation, optic nerve damage, delayed wound healing.

    Otic administration: Ear discomfort, ear pain, ear pruritus.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant